LOS ANGELES (MarketWatch) ��Gold futures moved nominally higher on Monday, keeping in a tight range as traders positioned themselves ahead of this week�� Federal Reserve meeting and what it could mean for the central bank�� bond-buying program.
Gold for February delivery (GCG4) �tacked on $1.10 to $1,235.70 an ounce, while March silver (SIH4) �gave up a penny to $19.59 an ounce.
AFP/Getty ImagesGold prices closed Friday�� session with a 0.5% gain for the week. The precious metal took a big hit on Thursday, as a budget deal was seen as the latest evidence pointing to the likely onset of a tapering of the Federal Reserve�� stimulus when the central bank meets this week.
Best Diversified Bank Stocks To Watch For 2015: Christopher & Banks Corporation (CBK)
Christopher & Banks Corporation, through its subsidiaries, operates retail stores that provide women�s apparel and accessories in the United States. The company designs, sources, and sells apparel catering to customers generally ranging in age from 45 to 60. Its stores offer knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrications, and dresses in various sizes, as well as jewelry and accessories. As of March 13, 2013, the company operated 605 stores in 44 states, including 381 Christopher & Banks stores, 158 C.J. Banks stores, 41 dual stores, and 25 outlet stores. It also operates e-Commerce Web sites christopherandbanks.com and cjbanks.com. The company was formerly known as Braun�s Fashions Corporation and changed its name to Christopher & Banks Corporation in July 2000. Christopher & Banks Corporation was founded in 1956 and is headquartered in Plymouth, Minnesota.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Christopher & Banks (NYSE: CBK ) , whose recent revenue and earnings are plotted below. - [By Dan Caplinger]
On Friday, Christopher & Banks (NYSE: CBK ) will release its latest quarterly results. With the company having recovered from the brink of failure a year ago, investors are wondering what the retailer still has planned to produce further growth.
- [By Sarah Jones]
Commerzbank (CBK) added 2.6 percent to 11.09 euros. Germany�� second-largest lender reported a first-quarter loss of 94 million euros after booking costs associated with firing staff, compared with a profit of 355 million euros a year earlier. That still beat the average loss estimate of 153.7 million euros of seven analysts surveyed by Bloomberg.
Best Net Payout Yield Companies To Invest In 2014: Spansion Inc(CODE)
Codere, S.A. engages in the management of gaming machines, bingo halls, horse racing tracks, casinos, and off-track betting facilities in Argentina, Brazil, Colombia, Italy, Mexico, Spain, Panama, and Uruguay. As of December 31, 2008, the company managed 54,818 slot machines and electronic bingo terminals, 137 bingo halls with 30,803 seats, 106 off-track betting facilities, 3 horse racing tracks, and 6 casinos. It also operated 15,963 AWP machines in approximately 10,886 bars and restaurants in Spain. Codere, S.A. was founded in 1980 and is headquartered in Alcobendas, Spain.
Advisors' Opinion:- [By Seth Jayson]
Spansion (NYSE: CODE ) reported earnings on April 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Spansion missed estimates on revenues and beat expectations on earnings per share.
Best Net Payout Yield Companies To Invest In 2014: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).
The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.
The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.
Advisors' Opinion:- [By Lauren Pollock]
ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.
- [By Wallace Witkowski]
Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.
- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
- [By Monica Gerson]
ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.
Posted-In: market losersNews Movers & Shakers Intraday Update Markets
Best Net Payout Yield Companies To Invest In 2014: Harmonic Inc.(HLIT)
Harmonic Inc. designs, manufactures, and sells video infrastructure products and system solutions to create, prepare, and deliver a range of video services for television and media platforms in the united States and internationally. Its products include video production platforms and playout solutions, such as video servers used by broadcasters, content owners, and multi-channel network operators to create and play-to-air television channels; video-optimized storage, which provides storage capacity and access bandwidth to support media production applications comprising video editing, content transformation, and media library management; and media applications that provide media integrated management and workflow control over content stored on its systems. The company offers video processing products, including broadcast encoders; contribution and distribution encoders; stream processing and statistical multiplexing solutions; content preparation and delivery for multi-scr een applications; decoders and descramblers; and management and control software. It also provides edge products that integrate routing, multiplexing, scrambling, and modulation into a single package; optical transmitters and amplifiers, which operates at various optical wavelengths and serves long-haul and local transport applications in the cable distribution network; optical nodes to supports network architectures for bandwidth delivered to a service area; and return path transmitters that support two-way transmission capabilities for analog or digital transport. In addition, the company offers technical support and professional services, such as maintenance and support; and consulting, implementation, and integration services. Harmonic Inc. sells its products through direct sales force, independent distributors, and integrators to cable, satellite and telco, and broadcast and media companies. The company was founded in 1988 and is headquartered in San Jose, California. Advisors' Opinion:
- [By Eddie Staley]
Shares of Harmonic (NASDAQ: HLIT) were down 13.46 percent to $6.18 after the company lowered its Q2 forecast and issued a weak Q3 guidance.
Riverbed Technology (NASDAQ: RVBD) shares tumbled 6.77 percent to $18.97 after the company lowered its Q2 revenue forecast.
- [By Seth Jayson]
Harmonic (Nasdaq: HLIT ) is expected to report Q1 earnings on April 23. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Harmonic's revenues will decrease -10.8% and EPS will decrease -66.7%. - [By Roberto Pedone]
Harmonic (HLIT) designs, manufactures and sells versatile and hig-performance video products and system solutions that enable service providers to efficiently deliver the next generation of broadcast and on-demand services. This stock closed up 1.8% to $7.81 in Tuesday's trading session.
Tuesday's Range: $7.61-$7.85
52-Week Range: $3.96-$8.04
Tuesday's Volume: 656,000
Three-Month Average Volume: 777,544From a technical perspective, HLIT bounced modestly higher here right above its 50-day moving average of $7.51 with decent upside volume. This stock has been uptrending a bit for the last month, with shares moving higher from its low of $7.10 to its intraday high of $7.85. During that move, shares of HLIT have been consistently making higher lows and higher highs, which is bullish technical price action. That move is now pushing shares of HLIT within range of triggering a big breakout trade. That trade will hit if HLIT manages to take out some near-term overhead resistance at $8 to its 52-week high at $8.04 with high volume.
Traders should now look for long-biased trades in HLIT as long as it's trending above its 50-day at $7.51 or above more support at $7, and then once it sustains a move or close above those breakout levels with volume that hits near or above 777,544 shares. If that breakout triggers soon, then HLIT will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that move are $9.50 to $10.50.
Best Net Payout Yield Companies To Invest In 2014: Home Loan Servicing Solutions Ltd (HLSS)
Home Loan Servicing Solutions, Ltd, incorporated on December 1, 2010, is a development-stage company. The Company is formed to acquire mortgage servicing assets, primarily subprime and Alt-A mortgage servicing rights and associated servicing advances. The Company will engage residential mortgage loan servicers to service the pools of mortgage loans underlying the mortgage servicing rights. The Company acquire and therefore do not intend to develop its own mortgage servicing platform.
The Company is focused to enter into the subservicing agreement to provide for the servicing of the initial mortgage servicing rights for an initial term of seven years. As of December 31, 2010, The Company had neither purchased nor contracted to purchase any mortgage servicing assets, including mortgage servicing rights and related servicing advances.
Advisors' Opinion:- [By Eric Volkman]
Home Loan Servicing Solutions (NASDAQ: HLSS ) is servicing its capital base with a new share offering that should total nearly $300 million. The company is floating 13 million shares of its stock in an underwritten public issue at a price of $23 per share. All told, the gross proceeds of the offering should amount to roughly $299 million.
- [By David Sterman]
Although shares of Boulder Brands (Nasdaq: BDBD) are up more than 60% since then, Home Loan Servicing (Nasdaq: HLSS) has merely treaded water while Swift Energy has continued its downward ascent.
No comments:
Post a Comment